Compare Boston Scientific Corporation (BSX) vs Stanley Black & Decker, Inc. (SWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Stanley Black & Decker, Inc. — how do they compare? Boston Scientific Corporation trades at $42.8 (market cap $66.37B), while Stanley Black & Decker, Inc. trades at $86.5 (market cap $13.58B). The key difference: Boston Scientific Corporation is far larger — about 4.9× Stanley Black & Decker, Inc.'s market cap, and Stanley Black & Decker, Inc. pays a 3.8% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SWK | |
|---|---|---|
Market Cap | $66.37B | $13.58B |
Sector | Health | — |
52-Week High | $108.14 | $94.12 |
52-Week Low | $42.63 | $62.12 |
Enterprise Value | $75.94B | $19.75B |
Dividend Yield | — | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Stanley Black & Decker (SWK) trades at $86.53, down 1.92% on the day, with a bearish technical signal but recent earnings beats. The company shows modest revenue of $15.13B in 2025 and a net income margin of 2.44%, though profitability metrics like ROE at 4.17% remain subdued. A dividend of $0.83 was recently declared, with cash flow from operations positive at $971.20M. Analyst consensus is mixed with 43% buy ratings but a price target below the current price.
SWK faces headwinds from weak Tools & Outdoor demand and high debt, though cost-saving efforts and aerospace growth offer upside. The stock's valuation at a P/E of 35.46 appears stretched relative to earnings growth, suggesting cautious optimism hinges on execution improvements and debt reduction. Risks include consumer sentiment and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →
